Search - tctmd.com

Displaying 601 - 620 of 3383

Sort: Relevancy | Date

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

Younger Age at AF Onset Linked to Greater Dementia Risk

News Daily News

Younger Age at AF Onset Linked to Greater Dementia Risk

Yael L. Maxwell

November 10, 2023

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

News Conference News AHA 2023

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

November 09, 2023

FDA Grants Tirzepatide a New Indication for Obesity Management

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

November 08, 2023

FDA Approves Paradise Renal Denervation System: What Comes Next?

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

November 08, 2023

Very High LDL Cholesterol Declines in US Adults, but Progress Is Slow

News Daily News

Very High LDL Cholesterol Declines in US Adults, but Progress Is Slow

Michael O'Riordan

November 02, 2023

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

News Conference News TCT 2023

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

Yael L. Maxwell

November 02, 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

News Conference News VIVA 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

November 01, 2023

TRILUMINATE Deep Dive Clarifies ‘Meaningful’ QoL Gains With Tricuspid TEER

News Conference News TCT 2023

TRILUMINATE Deep Dive Clarifies ‘Meaningful’ QoL Gains With Tricuspid TEER

Yael L. Maxwell

October 26, 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

News Conference News TCT 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

October 25, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

More TRILUMINATE Patients Flesh Out Tricuspid TEER’s Impact

News Conference News TCT 2023

More TRILUMINATE Patients Flesh Out Tricuspid TEER’s Impact

Yael L. Maxwell

October 24, 2023

OCT, IVUS Both Seem to Be Good Options for Complex Coronary Lesions

News Conference News TCT 2023

OCT, IVUS Both Seem to Be Good Options for Complex Coronary Lesions

October 23, 2023

Earlier Extraction for Cardiac Device Infections Tied to Lower Mortality

News Daily News

Earlier Extraction for Cardiac Device Infections Tied to Lower Mortality

October 20, 2023

SAVR 5-Year Survival Tops 92% in Low-Risk Patients: STS Registry

News Daily News

SAVR 5-Year Survival Tops 92% in Low-Risk Patients: STS Registry

Yael L. Maxwell

October 20, 2023

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

October 16, 2023

Surgeons Support Proposed Changes to Left Main CAD Guidelines

News Conference News EACTS 2023

Surgeons Support Proposed Changes to Left Main CAD Guidelines

Michael O'Riordan

October 13, 2023

Pooled Cohort Equations Work in Real-world Patients, Even Outliers

News Daily News

Pooled Cohort Equations Work in Real-world Patients, Even Outliers

Yael L. Maxwell

October 12, 2023

Dear Cardiologist: Think You Don’t Belong in Cardio-Reproductive Conversations? You’re Dead Wrong

News Opinion Off Script

Dear Cardiologist: Think You Don’t Belong in Cardio-Reproductive Conversations? You’re Dead Wrong

Rachel M. Bond, MD

October 11, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.